By David Bautz, PhD NASDAQ:DWTX READ THE FULL DWTX RESEARCH REPORT Business Update First Patient Dosed in Phase 2b Trial of Halneuron® On March 18, 2025, Dogwood Therapeutics, Inc. (NASDAQ:DWTX) announced that the first patient was dosed in the Phase 2b HALT-CINP (Halneuron Treatment of Chemotherapy-Induced Neuropathic Pain) trial. This is a four-week study that … Read more
By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer On March 24, 2025, Imunon, Inc. (NASDAQ:IMNN) announced it reached alignment with the U.S. FDA on the protocol for a Phase 3 clinical trial, referred to as OVATION 3, of … Read more
By David Bautz, PhD NASDAQ:CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Collaboration Agreement with Abbott for Phase 3 TECH-LVAD Trial On March 4, 2025, Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced a collaboration agreement with Abbott for the Phase 3 TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial. In August 2024, Cadrenal … Read more
An attorney for a Texas pipeline company said Wednesday at trial that he will prove various Greenpeace entities coordinated delays and disruptions of a controversial oil pipeline’s construction in North Dakota, and defamed the company to its lenders. Attorneys for the Greenpeace defendants told a jury there is no evidence to back up the claims … Read more
A Adam Raga Sans (Ulldecona, Tarragona; 42 años) se le hará extraño dejar de una vez por todas la competición. Aunque es una decisión meditada desde el pasado verano, la intención de despedirse en casa, ante el público de la 48º edición del Trial Indoor de Barcelona, le ha obligado a mantenerse en plena forma … Read more